On July 10, 2025, Salarius Pharmaceuticals received an extension from Nasdaq to regain compliance with listing rules, needing to meet these requirements by late July and early August 2025. This follows a prior notice regarding non-compliance due to its stock price being below $1.00 for 30 consecutive business days.